Insmed's revenue climbed from $92.8M in 2025Q1 to $524.4M in 2026Q3, suggesting genuine commercial uptake and high gross margins near 85% that point to orphan-drug pricing power.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew to $524.4M in 2026Q3 with gross margin of 85.1%, yet operating margin of -17.0% and a net loss of $100.3M suggest operating expenses of roughly $523M still outpace gross profit.
Brensocatib's FDA approval in February 2026 and Q1/2026 sales exceeding expectations by 2× validate the bullish investment thesis.
Encouraging post-hoc Phase III data for Brinsupri, a first-to-market DPP-1 inhibitor, presented at the American Thoracic Society conference strengthens the bull case.
Insmed's grant of inducement stock awards to 103 new employees under its 2025 Inducement Plan signals growth and commitment to scaling operations.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | -$0.46-20.2% vs -$0.38 | $524M+4.8% vs $500M |
Q3 2026 Aug 6, 2026 | -$0.06+91.1% vs -$0.67 | $425M+7.6% vs $395M |
Q2 2026 May 7, 2026 | -$0.76+21.1% vs -$0.96 | $306M+1.7% vs $301M |
Q1 2026 Feb 19, 2026 | -$1.54-43.9% vs -$1.07 | $264M+14.1% vs $231M |
Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades landing on names that have struggled all year.
BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 2:00 p.m.
Insmed Incorporated ( INSM ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants William Lewis - President, CEO & Chairman Sara Bonstein Martina Flammer - Chief Medical Officer Conference Call Participants Yesha Patel - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Faisal Khurshid - Jefferies LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Ritu Baral - TD Cowen, Research Division Jason Zemansky - BofA Securities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Maxwell Skor - Morgan Stanley, Research Division Leonid Timashev - RBC Capital Markets, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the Insmed Third Quarter 2026 Financial Results Conference Call.
Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
Benchmark INSM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Insmed Incorporated (INSM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $114.41 | $24.8B | -41.33 | 66.73% | -39.85% | -82.75% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $155.94 | $20.82B | 7.90 | 65.19% | 54.34% | 159.72% | — | |
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — |
Insmed Incorporated (INSM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Insmed Incorporated (INSM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 20, 2026·SEC
Oct 5, 2026·SEC
Get notified when INSM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Insmed Incorporated (INSM) stock FAQ — growth, dividends, profitability & financials explained
Insmed Incorporated (INSM) reported $1.52B in revenue over the trailing twelve months. Revenue was $606.4M in fiscal year 2025. That is 60642200% more than the $0.0M of fiscal year 1999.
Insmed Incorporated (INSM) grew revenue by 240.0% over the trailing twelve months, compared with the twelve months before.
No. Insmed Incorporated (INSM) reported a net loss of $605.6M over the trailing twelve months.
Insmed Incorporated (INSM) had a return on equity (ROE) of -82.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Insmed Incorporated (INSM) had negative free cash flow of $657.6M over the trailing twelve months.
